Back to Search
Start Over
Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
- Source :
- Cancer Medicine, Vol 12, Iss 10, Pp 11513-11524 (2023)
- Publication Year :
- 2023
- Publisher :
- Wiley, 2023.
-
Abstract
- Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD‐1 inhibitors (T‐L‐P) versus TACE combined with lenvatinib (T‐L) or TACE alone. Method Data were collected from 204 patients with unresectable recurrent HCC who received T‐L‐P, T‐L, or TACE alone at three medical centers from January, 2019 to December, 2020 for analysis. The survival outcomes, tumor response, and adverse events were compared between three groups, and risk factors were further investigated. Results The median overall survival in the T‐L‐P, T‐L, and TACE alone groups were not reached, 25.6, and 15.7 months, respectively (p
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 12
- Issue :
- 10
- Database :
- Directory of Open Access Journals
- Journal :
- Cancer Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6862c0cf51ad41c4a4df7fb2b3c55385
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/cam4.5880